Main Article Content
Metformin is the widely prescribed first line oral antidiabetic drug used in diabetes mellatus, type 2 . The global sales turnover of metformin runs into millions of dollars. The Increased risk of metformin (Met) users for developing Alzheimer disease (AD)is reported first in a study conducted in 2011. Since then, the subject has attracted the attention of the researchers as well as the pharmaceutical industry, resulting in a number of studies, both clinical as well as experiments on animals. Confusing results poured in , ranging from confirmation of the risk of AD to protection against developing AD , making the scenario, all the more intriguing . Added to the confusion, is the diversity of various studies as well as the parameters interpreting their results. Of the many clinical trials, some are retrospective cohort studies (Tseng Chin-Hsiao 2019) , case control studies (Imfeld P, et al.) Randomised studies (Hsu CC, et al.), double blind , cross over pilot studies. (Aaron Koenig et al.) and some longitudinal studies (Ng TP, et al.) , besides studies doing meta analysis . Of these studies most of the trials estimate the risk of development of dementia with metformin alone (Tseng Chin-Hsiao 2019) or in comparison with other OHAs (Hsu et al, Cheng et al.) .The other studies studied the effect of metformin on the cognition. (Moore EM, et al.). These trials have different out come measures, (like Hazard ratio, (HR) Odds(OR) ratio, relative risk (RR) etc.) which don’t mean one and the same. So the multiplicity of the types of studies and different out- comes with different conclusions will be surely baffling to an average reader who tries to take cognisance of the involved issues. The article attempts to take stock of the overall developments in this regard. The author adopted a reader friendly approach which is discussed in the article, at the outset. Finally, it is reiterated that future prospective studies only can resolve the conflict of opinion on the nexus between metformin and Alzheimer’s disease.
Chin-Hsiao T. Metformin and the risk of dementia in type 2 diabetes patients. Aging Dis. 2019;10(1):37-48.
Albanese E, Launer LJ, Egger M, Prince MJ, Giannakopoulos P, Wolters FJ, et al. Body mass index in midlife and dementia: Systematic review and meta-regression analysis of 589,649 men and women followed in longitudinal studies. Alzheimers Dement (Amst). 2017;8:165-78.
Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ, 2010;340:b5087.
Wennberg AMV, Hagen CE, Edwards K, Roberts RO, Machulda MM, Knopman DS, Petersen RC, Mielke MM. Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging. International Journal of Geriatric Psychiatry. 2018;33(8):1114-1120.
Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: A population-based case-control study. J Am Geriatr Soc. 2012;60:916-21.
Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B. Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimer’s Dis. 2014;41: 61-
Moor EM, et Increased risk of cognitive d in patients with diabetes is associated with metformin al. Diabetes Diabetes Care; 2013.
Jared M. Campbell, Matthew D. Stephenson and Edoardo Aromataris. Metformin use associated with reduced risk of dementia in patients with diabetes: A systematic review and meta-analysis J. Alzheimer’s Dis; 2018.
Ariela R. Orkaby, Kelly Cho and Jane A. Driver. Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes. Neurology. 2017; 89(18):1877–1885.
Aaron Koenig et al. Effects of the insulin sensitizer metformin in alzheimer disease: Pilot data from a randomized placebo-controlled crossover study. Alzheimer Disease and Associated D. 2017;31(2): 107-113. [Isorders]
Cheng C, Lin CH, Tsai YW, Tsai CJ, Chou PH, Lan TH. Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis. J Gerontol A Biol Sci Med Sci. 2014;69:1299-305.
Deborah Brauser: Increased dementia, Parkinson’s. Risk in patients with diabetes. Mediscape; 2017.
Ned Sacktor, Anja Soldan, et al. The BIOCARD index: A summary measure to predict onset of mild cognitive Impairment ned sacktor, Anja Soldan, et al. The BIOCARD index: A summary measure to predict onset of mild cognitive impairment Alzheimer Dis Assoc! 2017;31(2):114–119. Ned Sacktor, Anja Soldan, et al.
Fujita H, Fujishima H, Morii T, Koshimura J, Narita T, Kakei M, et al. Effect of metformin on adipose tissue resistin expression in db/db mice. Biochem Biophys Res Commun. 2002;298:345–9.
Kim B, Backus C, Oh S, Hayes JM, Feldman EL. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology. 2009;150:5294–301.
Kawasaki F, Matsuda M, Kanda Y, Inoue H, Kaku K. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am J Physiol Endocrinol Metab. 2005;288: E510–8.
Oomura Y, Hori N, Shiraishi T, Fukunaga K, Takeda H, Tsuji M, et al. Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats. Peptides. 2006;27:2738–49.